All In Biotech

Drug Trial Radar · NCT04784715

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,157 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,157

Actual

Start

Apr 26, 2021

Primary completion

May 3, 2027

Study completion Dec 31, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Mar 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment in the metastatic setting.

Conditions

  • Breast Cancer; HER2-positive; Metastatic

Interventions

  • Trastuzumab deruxtecanDrug

    Administered by intravenous infusion

  • PlaceboDrug

    Administered by intravenous infusion

  • TaxaneDrug

    Investigator's choice of docetaxel or paclitaxel administered by intravenous infusion

  • PertuzumabDrug

    Administered by intravenous infusion

  • TrastuzumabDrug

    Administered by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessmentTime frame: Until progression or death, assessed up to approximately 60 months

Locations

283 sites in 27 countries. Site status is shown where the registry gives one.

  • Research Site

    Tucson, Arizona

  • Research Site

    Springdale, Arkansas

  • Research Site

    Glendale, California

  • Research Site

    Glendale, California

  • Research Site

    Longmont, Colorado

  • Research Site

    Miami, Florida

  • Research Site

    Palm Bay, Florida

  • Research Site

    Plantation, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Louisville, Kentucky

  • Research Site

    Silver Spring, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Detroit, Michigan

  • Research Site

    Jackson, Mississippi

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Summit, New Jersey

  • Research Site

    New York, New York

  • Research Site

    Shirley, New York

  • Research Site

    York, Pennsylvania

  • Research Site

    Germantown, Tennessee

  • Research Site

    Dallas, Texas

  • Research Site

    Dallas, Texas

  • Research Site

    Denton, Texas

  • Research Site

    Houston, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Shenandoah, Texas

  • Research Site

    Tyler, Texas

  • Research Site

    Norfolk, Virginia

  • Research Site

    Roanoke, Virginia

  • Research Site

    Tacoma, Washington

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Caba, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    Capital Federal, Argentina

  • Research Site

    Cipolletti, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    La Plata, Argentina

  • Research Site

    Mar del Plata, Argentina

  • Research Site

    Rosario, Argentina

Showing 40 of 283 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.